Rhythm announced a strategic partnership agreement with Trispera Pharma Solutions in Turkey.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Analyst Recommends Buy Rating for Rhythm Pharmaceuticals Due to Setmelanotide’s Potential in Hypothalamic Obesity Market
- Optimistic Outlook for Rhythm Pharmaceuticals: Imcivree’s Promise in Treating Hypothalamic Obesity
- Is RYTM a Buy, Before Earnings?
- Buy Recommendation for Rhythm Pharmaceuticals: Promising Potential of Imcivree in Obesity Treatment
- Rhythm Pharmaceuticals: Promising Weight Loss Breakthroughs and Strategic Advancements Justify Buy Rating